The 340B program “attracts hospitals, clinics and for-profit pharmacies because it is easy for them to use the program as a slush fund to benefit their bottom lines, diverting money that could be used to help patients get better care and afford their medicines,” Pharmaceutical Research and Manufacturers of America (PhRMA) Senior Director of Public Affairs Nicole Longo wrote yesterday in the association’s blog.
“We must stop abuses of the 340B program by covered entities who put profits before patients,” Longo said in the blog. “That’s why biopharmaceutical companies are advocating for meaningful improvements to the program that ensure patients directly benefit from the tens of billions of dollars in discounts that manufacturers provide. Covered entities must be held accountable for how they use 340B discounts through increased government oversight and transparency requirements to make the 340B program sustainable in the long term.”
The 340B program “attracts hospitals, clinics and for-profit pharmacies because it is easy for them to use the program as a slush fund to benefit their bottom lines, diverting money that could be used to help patients get better care and afford their medicines,” Pharmaceutical Research and Manufacturers of America (PhRMA) Senior Director of Public Affairs Nicole Longo wrote yesterday in the association’s blog.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
